Cambridge Innovation Capital
Investing in technology and healthcare companies in the Cambridge Cluster.
|Address:||The Hauser Forum, 3 Charles Babbage Road, Cambridge|
Cambridge Innovation Capital (“CIC”) invests in intellectual property rich companies in the Cambridge Cluster, combining a unique relationship with the University of Cambridge with deep financial and industry links to the area. The company strives to build leading businesses using a long term return strategy - removing the pressure to deliver the early exits associated with the traditional venture capital model.
CIC is led by an experienced investment team, an outstanding board and advisory panel of leading scientists and entrepreneurs, backed by long term institutional and strategic investors.
CIC has an unrivalled appreciation for world-leading scientific development given its position within the Cambridge Cluster. The company is committed to ensuring that its investment partners can build leading businesses from brilliant technologies - with the support of some of the most influential figures in the sector.
The big challenge for developers of autonomous vehicles is ensuring that they operate effectively in the real world. To tackle this and similar challenges, Cambridge start-up PROWLER.io has raised £10 million in a series A funding round led by Cambridge Innovation Capital (CIC).
5 September 2017Read in full
Cambridge Innovation Capital (CIC) announces highlights from its annual results for the year ended 31 March 2017.
6 July 2017Read in full
The top blockbuster drug for 2016 was based on the techniques developed by Professor Sir Gregory Winter. Now his latest Cambridge company, Bicycle Therapeutics, has gained £40 million from investors including Cambridge Innovation Capital.
1 June 2017Read in full
Cambridge Innovation Capital (CIC), a Cambridge-based investor in technology and healthcare companies, announces that its CEO, Victor Christou, will be presenting at the Global University Venturing: Fusion event in London this evening (Weds).
24 May 2017Read in full
Seventy-five per cent of patients with a rare disease are children. Cambridge-based Congenica has a world-leading technology that offers a rapid diagnosis. Already in clinical use in the UK, the company has raised £8 million to fund its international expansion.
27 February 2017Read in full
Cambridge Innovation Capital plc is pleased to announce the appointment of Dr Michael Anstey as an Investment Director specialising in healthcare investments.
31 January 2017Read in full
The creation of Microbiotica Ltd, a newly formed spin-out company from the UK’s Wellcome Trust Sanger Institute based at the Wellcome Genome Campus in Hinxton, Cambridge, has been announced by Cambridge Innovation Capital plc (CIC), a Cambridge-based investor in technology and healthcare companies, and IP Group plc, the developer of intellectual property-based businesses.
20 December 2016Read in full
Cambridge Innovation Capital plc (CIC), a Cambridge-based investor in technology and healthcare companies, is pleased to announce the appointment of Dr Andrew Williamson as an Investment Director.
7 December 2016Read in full
Cambridge Innovation Capital plc has committed £19 million to six investments since raising £75 million in August 2016. The £75 million funding round increased CIC’s funds under management to £125 million. CIC has provided funding to three existing portfolio companies, Imagen, PragmatIC Printing and Undo, and three new businesses, Carrick Therapeutics, Fluidic Analytics and PervasID.
3 November 2016Read in full